MBC rebrands as Digitas Health

Share this article:
Philadelphia-based interactive healthcare agency Medical Broadcasting Company (MBC) has introduced a new name -- Digitas Health. With the move, the renamed firm closer aligns itself with its parent agency, the consumer digital firm Digitas, which purchased the firm in January 2006. Digitas was acquired by Publicis Groupe in a $1.3 billion deal in December 2006. Digitas Health will be led by CEO David Kramer, a co-founder of MBC, who will report to Digitas president Laura Lang. “We’re completing the mission that (Digitas CEO) David Kenny and I had at the very beginning when they first acquired MBC,” Kramer told MM&M. Digitas Health will remain headquartered in Philadelphia, Kramer said. The firm however will begin to work to unify the healthcare practices across all of the Digitas offices, which include locations in New York, Boston and Chicago. “Over time we will be hiring aggressively in all of those cities and setting ourselves up for very substantial growth,” Kramer added.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...